Literature DB >> 26636496

Phosphatidylethanolamine N-methyltransferase gene rs7946 polymorphism plays a role in risk of nonalcoholic fatty liver disease: evidence from meta-analysis.

Hwa-Li Tan1, Rosmawati Mohamed, Zahurin Mohamed, Shamsul Mohd Zain.   

Abstract

BACKGROUND: Phosphatidylethanolamine N-methyltransferase (PEMT) governs the secretion of hepatic triglycerides in the form of very low-density lipoprotein and has been implicated in nonalcoholic fatty liver disease (NAFLD). Studies on the role of the PEMT rs7946 polymorphism as a genetic modifier of NAFLD have reported inconsistent results. This meta-analysis was carried out to evaluate and summarize the association of PEMT rs7946 with susceptibility to NAFLD.
METHODS: A comprehensive literature search in Scopus, PubMed, Embase, Science Direct and Google Scholar was performed up to 31 August 2015, followed by data extraction and examination of summary estimates.
RESULTS: Six independent studies with a total of 792 NAFLD cases and 2722 controls fulfilled the inclusion criteria. Pooled results indicated that the rs7946 A-allele was associated significantly with an increased risk of NAFLD [odds ratio (OR) 1.55, 95% confidence interval (CI) 1.14-2.11, P=0.005]. A significant association was also found in alternative genetic models of inheritance: dominant, recessive and homozygote (OR 1.62, 95% CI 1.10-2.39, P=0.01; OR 1.42, 95% CI 1.12-1.81, P=0.003; and OR 1.64, 95% CI 1.18-2.29, P=0.004, respectively). Subgroup analysis by ethnicity indicated a significant association only in the East-Asians in the additive (OR=2.08, 95% CI 1.12-3.86, P=0.02), recessive (OR=2.94, 95% CI 1.60-5.37, P=0.0005) and homozygote (OR=1.86, 95% CI 1.15-3.01, P=0.01) models.
CONCLUSION: This study provides evidence of a significant association between the PEMT rs7946 A-allele and a risk of NAFLD, with the effect being more prominent in East-Asians, but not in non-Asians.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26636496     DOI: 10.1097/FPC.0000000000000193

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN: 1744-6872            Impact factor:   2.089


  6 in total

Review 1.  Potential Therapeutic Targets and Promising Agents for Combating NAFLD.

Authors:  Atsushi Umemura; Seita Kataoka; Keiichiro Okuda; Yuya Seko; Kanji Yamaguchi; Michihisa Moriguchi; Takeshi Okanoue; Yoshito Itoh
Journal:  Biomedicines       Date:  2022-04-14

Review 2.  Metabolic aspects of adult patients with nonalcoholic fatty liver disease.

Authors:  Ludovico Abenavoli; Natasa Milic; Laura Di Renzo; Tomislav Preveden; Milica Medić-Stojanoska; Antonino De Lorenzo
Journal:  World J Gastroenterol       Date:  2016-08-21       Impact factor: 5.742

Review 3.  Nonalcoholic fatty liver disease and cardiovascular disease phenotypes.

Authors:  Giandomenico Bisaccia; Fabrizio Ricci; Cesare Mantini; Claudio Tana; Gian Luca Romani; Cosima Schiavone; Sabina Gallina
Journal:  SAGE Open Med       Date:  2020-06-20

Review 4.  Choline and choline-related nutrients in regular and preterm infant growth.

Authors:  Wolfgang Bernhard; Christian F Poets; Axel R Franz
Journal:  Eur J Nutr       Date:  2018-10-08       Impact factor: 5.614

Review 5.  Genetics of Non-Alcoholic Fatty Liver and Cardiovascular Disease: Implications for Therapy?

Authors:  Karthik Chandrasekharan; William Alazawi
Journal:  Front Pharmacol       Date:  2020-01-08       Impact factor: 5.810

6.  Optimal Dietary Intake Composition of Choline and Betaine Is Associated with Minimized Visceral Obesity-Related Hepatic Steatosis in a Case-Control Study.

Authors:  Ting-Yu Chang; Chien-Hsien Wu; Chi-Yang Chang; Fu-Jen Lee; Bei-Wen Wang; Jia-Yau Doong; Yu-Shun Lin; Chang-Sheng Kuo; Rwei-Fen S Huang
Journal:  Nutrients       Date:  2022-01-08       Impact factor: 5.717

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.